Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jul;118(5):1223–1231. doi: 10.1111/j.1476-5381.1996.tb15527.x

Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.

M Giral 1, D Balsa 1, R Ferrando 1, M Merlos 1, J Garcia-Rafanell 1, J Forn 1
PMCID: PMC1909590  PMID: 8818347

Abstract

1. The effects of the selective and potent novel platelet-activating factor (PAF) antagonist, UR-12633 (1-(3,3-diphenylpropionyl)-4-(3-pyridylcyanomethyl)piperidin e) on several markers of endotoxic shock syndrome were evaluated in rats and mice. 2. UR-12633, administered 60 min after E. coli lipopolysaccharide (LPS), reversed the LPS-induced sustained hypotension in rats at doses of 0.01 to 1 mg kg-1, i.v. The reference compound WEB-2086 (1 mg kg-1) also reversed the LPS-induced hypotension. UR-12633 (1 mg kg-1), administered 10 min before LPS, almost fully inhibited sustained hypotension. The immediate hypotension (within 1 min) caused by LPS was not prevented by either UR-12633 or WEB-2086. 3. Pretreatment with 10 mg kg-1, i.v. of either UR-12633 or WEB-2086 inhibited the increase in disseminated intravascular coagulation markers, such as activated partial thromboplastin time (55 and 74% inhibition, respectively), and prothrombin time (22 and 72% inhibition) and prevented the decrease in plasma fibrinogen content (100 and 29% inhibition). 4. Increases in acid phosphatase (ACP) plasma activity, a marker of lysosomal activation, and in lactate dehydrogenase (LDH), a marker of tissue damage, were inhibited by pretreatment with 10 mg kg-1, i.v. of either UR-12633 or WEB-2086 (100% and 69% inhibition, ACP; 62 and 48% inhibition, LDH). Hyperglycaemia (71 and 46%) and hyperlactacidaemia (92 and 56%) were also inhibited. 5. UR-12633, but not WEB-2086, inhibited the LPS-induced increase in vascular permeability in rats, as shown by prevention of haemoconcentration and, to a lesser degree, the increase in Evans blue dye extravasation. 6. In a series of nine reference compounds and UR-12633, we found a high correlation (P < 0.001) between PAF antagonist activity, measured as the inhibition of PAF-induced rabbit platelet aggregation or PAF-induced mortality in mice and the inhibition of LPS-induced mortality. 7. In spite of the multifactorial nature of endotoxic shock, in which many mediators may be involved, the new potent PAF antagonist, UR-12633, proved effective in protecting against changes in most shock markers. These data strongly suggest a key role for PAF in the pathogenesis of endotoxic shock in rodents.

Full text

PDF
1223

Images in this article

1226Figure 4
on p.1226

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. Brecht H. M., Adamus W. S., Heuer H. O., Birke F. W., Kempe E. R. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. Arzneimittelforschung. 1991 Jan;41(1):51–59. [PubMed] [Google Scholar]
  3. Chang S. W., Feddersen C. O., Henson P. M., Voelkel N. F. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest. 1987 May;79(5):1498–1509. doi: 10.1172/JCI112980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Danner R. L., Elin R. J., Hosseini J. M., Wesley R. A., Reilly J. M., Parillo J. E. Endotoxemia in human septic shock. Chest. 1991 Jan;99(1):169–175. doi: 10.1378/chest.99.1.169. [DOI] [PubMed] [Google Scholar]
  5. Doebber T. W., Wu M. S., Robbins J. C., Choy B. M., Chang M. N., Shen T. Y. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem Biophys Res Commun. 1985 Mar 29;127(3):799–808. doi: 10.1016/s0006-291x(85)80014-0. [DOI] [PubMed] [Google Scholar]
  6. Emeis J. J., Kluft C. PAF-acether-induced release of tissue-type plasminogen activator from vessel walls. Blood. 1985 Jul;66(1):86–91. [PubMed] [Google Scholar]
  7. Evans T. W., Dent G., Rogers D. F., Aursudkij B., Chung K. F., Barnes P. J. Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man. Br J Pharmacol. 1988 May;94(1):164–168. doi: 10.1111/j.1476-5381.1988.tb11511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fleming I., Dambacher T., Busse R. Endothelium-derived kinins account for the immediate response of endothelial cells to bacterial lipopolysaccharide. J Cardiovasc Pharmacol. 1992;20 (Suppl 12):S135–S138. doi: 10.1097/00005344-199204002-00038. [DOI] [PubMed] [Google Scholar]
  9. Harlan J. M., Harker L. A., Reidy M. A., Gajdusek C. M., Schwartz S. M., Striker G. E. Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab Invest. 1983 Mar;48(3):269–274. [PubMed] [Google Scholar]
  10. Hosford D. J., Domingo M. T., Chabrier P. E., Braquet P. Ginkgolides and platelet-activating factor binding sites. Methods Enzymol. 1990;187:433–446. doi: 10.1016/0076-6879(90)87050-d. [DOI] [PubMed] [Google Scholar]
  11. Hurley J. C. Reappraisal of the role of endotoxin in the sepsis syndrome. Lancet. 1993 May 1;341(8853):1133–1135. doi: 10.1016/0140-6736(93)93139-r. [DOI] [PubMed] [Google Scholar]
  12. Ikegami K., Meade C. J., Heuer H. O., Birke F. Hetrazepine PAF antagonists. J Lipid Mediat. 1992 Jun-Jul;5(2):177–182. [PubMed] [Google Scholar]
  13. Imura Y., Terashita Z., Nishikawa K. Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988. Life Sci. 1986 Jul 14;39(2):111–117. doi: 10.1016/0024-3205(86)90444-3. [DOI] [PubMed] [Google Scholar]
  14. Iñarrea P., Gomez-Cambronero J., Nieto M., Crespo M. S. Characteristics of the binding of platelet-activating factor to platelets of different animal species. Eur J Pharmacol. 1984 Oct 15;105(3-4):309–315. doi: 10.1016/0014-2999(84)90623-x. [DOI] [PubMed] [Google Scholar]
  15. Katori M., Majima M., Odoi-Adome R., Sunahara N., Uchida Y. Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats. Br J Pharmacol. 1989 Dec;98(4):1383–1391. doi: 10.1111/j.1476-5381.1989.tb12688.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kawamura M., Terashita Z., Imura Y., Shino A., Nishikawa K. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. Thromb Res. 1993 May 15;70(4):281–293. doi: 10.1016/0049-3848(93)90101-s. [DOI] [PubMed] [Google Scholar]
  17. Koltai M., Hosford D., Guinot P., Esanu A., Braquet P. PAF. A review of its effects, antagonists and possible future clinical implications (Part II). Drugs. 1991 Aug;42(2):174–204. doi: 10.2165/00003495-199142020-00002. [DOI] [PubMed] [Google Scholar]
  18. Koltai M., Hosford D., Guinot P., Esanu A., Braquet P. Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part I). Drugs. 1991 Jul;42(1):9–29. doi: 10.2165/00003495-199142010-00002. [DOI] [PubMed] [Google Scholar]
  19. Lang C. H., Dobrescu C., Hargrove D. M., Bagby G. J., Spitzer J. J. Platelet-activating factor-induced increases in glucose kinetics. Am J Physiol. 1988 Feb;254(2 Pt 1):E193–E200. doi: 10.1152/ajpendo.1988.254.2.E193. [DOI] [PubMed] [Google Scholar]
  20. Meyrick B. O., Ryan U. S., Brigham K. L. Direct effects of E coli endotoxin on structure and permeability of pulmonary endothelial monolayers and the endothelial layer of intimal explants. Am J Pathol. 1986 Jan;122(1):140–151. [PMC free article] [PubMed] [Google Scholar]
  21. Morrison D. C., Ryan J. L. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417–432. doi: 10.1146/annurev.me.38.020187.002221. [DOI] [PubMed] [Google Scholar]
  22. Parrillo J. E. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993 May 20;328(20):1471–1477. doi: 10.1056/NEJM199305203282008. [DOI] [PubMed] [Google Scholar]
  23. Qi M., Jones S. B. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ Shock. 1990 Oct;32(2):153–163. [PubMed] [Google Scholar]
  24. Rabinovici R., Esser K. M., Lysko P. G., Yue T. L., Griswold D. E., Hillegass L. M., Bugelski P. J., Hallenbeck J. M., Feuerstein G. Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res. 1991 Jul;69(1):12–25. doi: 10.1161/01.res.69.1.12. [DOI] [PubMed] [Google Scholar]
  25. Ring P. C., Seldon P. M., Barnes P. J., Giembycz M. A. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation. Mol Pharmacol. 1993 Feb;43(2):302–312. [PubMed] [Google Scholar]
  26. Rylander R., Beijer L. Inhalation of endotoxin stimulates alveolar macrophage production of platelet-activating factor. Am Rev Respir Dis. 1987 Jan;135(1):83–86. doi: 10.1164/arrd.1987.135.1.83. [DOI] [PubMed] [Google Scholar]
  27. Szabó C., Mitchell J. A., Thiemermann C., Vane J. R. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol. 1993 Mar;108(3):786–792. doi: 10.1111/j.1476-5381.1993.tb12879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Szabó C., Wu C. C., Mitchell J. A., Gross S. S., Thiemermann C., Vane J. R. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res. 1993 Dec;73(6):991–999. doi: 10.1161/01.res.73.6.991. [DOI] [PubMed] [Google Scholar]
  29. Taveira da Silva A. M., Kaulbach H. C., Chuidian F. S., Lambert D. R., Suffredini A. F., Danner R. L. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med. 1993 May 20;328(20):1457–1460. doi: 10.1056/NEJM199305203282005. [DOI] [PubMed] [Google Scholar]
  30. Thompson W. A., Coyle S., Van Zee K., Oldenburg H., Trousdale R., Rogy M., Felsen D., Moldawer L., Lowry S. F. The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch Surg. 1994 Jan;129(1):72–79. doi: 10.1001/archsurg.1994.01420250084011. [DOI] [PubMed] [Google Scholar]
  31. Whittle B. J., Boughton-Smith N. K., Hutcheson I. R., Esplugues J. V., Wallace J. L. Increased intestinal formation of Paf in endotoxin-induced damage in the rat. Br J Pharmacol. 1987 Sep;92(1):3–4. doi: 10.1111/j.1476-5381.1987.tb11287.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. van Deventer S. J., Büller H. R., ten Cate J. W., Aarden L. A., Hack C. E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990 Dec 15;76(12):2520–2526. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES